ClinicalTrials.gov record
Terminated Phase 3 Interventional

Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)

ClinicalTrials.gov ID: NCT02410356

Public ClinicalTrials.gov record NCT02410356. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 6:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Open-Label, Comparator-Controlled Study to Assess Safety and Tolerability of Weekly TV-1106 Compared to Daily rhGH (Genotropin(R)) in Adults With Growth Hormone-Deficiency

Study identification

NCT ID
NCT02410356
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Enrollment
34 participants

Conditions and interventions

Interventions

  • TV-1106 Drug
  • dGH Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 29, 2015
Primary completion
Feb 28, 2016
Completion
Apr 29, 2016
Last update posted
Dec 9, 2021

2015 – 2016

United States locations

U.S. sites
32
U.S. states
12
U.S. cities
25
Facility City State ZIP Site status
Teva Investigational Site 13137 Artesia California 90701
Teva Investigational Site 13166 Fountain Valley California 33155-6541
Teva Investigational Site 13165 Lakewood California 90712
Teva Investigational Site 13155 Denver Colorado 80209
Teva Investigational Site 13158 Newark Delaware 19713
Teva Investigational Site 13162 Fort Lauderdale Florida 33312
Teva Investigational Site 13136 Homestead Florida 33030
Teva Investigational Site 13138 Miami Florida 33126
Teva Investigational Site 13152 Miami Florida 33130
Teva Investigational Site 13161 Miami Florida 33145
Teva Investigational Site 13500 Miami Florida 33155-6541
Teva Investigational Site 13503 Miami Florida 33175
Teva Investigational Site 13148 Miami Lakes Florida 33016
Teva Investigational Site 13134 Pembroke Pines Florida 33024
Teva Investigational Site 13129 West Palm Beach Florida 33401
Teva Investigational Site 13135 Detroit Michigan 48202
Teva Investigational Site 13146 Henderson Nevada 89052
Teva Investigational Site 13147 Las Vegas Nevada 89148
Teva Investigational Site 13143 Brooklyn New York 11235
Teva Investigational Site 13502 New York New York 10016
Teva Investigational Site 13140 New York New York 10032
Teva Investigational Site 13128 Asheville North Carolina 28803
Teva Investigational Site 13142 Pittsburgh Pennsylvania 15212
Teva Investigational Site 13144 Arlington Texas 76014
Teva Investigational Site 13163 Dallas Texas 75218
Teva Investigational Site 13130 Houston Texas 77079
Teva Investigational Site 13141 Houston Texas 77084
Teva Investigational Site 13154 Houston Texas 77090
Teva Investigational Site 13159 Norfolk Virginia 23507
Teva Investigational Site 13504 Federal Way Washington 98003
Teva Investigational Site 13164 Seattle Washington 98122
Teva Investigational Site 13157 Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02410356, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 9, 2021 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02410356 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →